Brief: Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)

Palvella Therapeutics

10/02/2025 13:10

Feb 10 (Reuters) - Palvella Therapeutics  PVLA.O :
    * PALVELLA THERAPEUTICS TO EXPAND PHASE 3 SELVA CLINICAL
TRIAL OF
QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE
TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS TO INCLUDE THE
YOUNGER PEDIATRIC POPULATION, CHILDREN 3 TO 5 YEARS OLD
    * PALVELLA THERAPEUTICS INC - TO REPORT PHASE 3 TRIAL
RESULTS IN
Q1 2026

Source text:  ID:nGNX6B2g7s 
Further company coverage:  PVLA.O 

 ((Reuters.Briefs@thomsonreuters.com;))